http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e10b41070559ff8050cec515a840a822
Outgoing Links
| Predicate | Object |
|---|---|
| family-name | Raynaud |
| name | Florence I Raynaud Florence I. Raynaud |
| given-name | Florence I. Florence I |
| organization-name | Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, United Kingdom Cancer Research UK Cancer Therapeutics Unit Division of Cancer Therapeutics The Institute of Cancer Research London UK 10Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. Drug Metabolism Pharmacokinetics and Metabolomics Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research Division of Cancer Therapeutics 15 Cotswold Road Sutton London SM2 5NG UK Drug Metabolism Pharmacokinetics and Metabolomics group, Cancer Research UK Cancer Therapeutics Unit, The Institute for Cancer Research, 15 Cotswold Road, Sutton Surrey, SM2 5NG, U.K. Piramed Pharma, 957 Buckingham Avenue, Slough, Berks SL1 4NL, United Kingdom, Genentech, Inc., 1 DNA Way, South San Francisco, California 94080, Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddon Laboratories, Sutton, Surrey, SN2 5NG, United Kingdom and Breakthrough Breast Cancer Research Centre, The Institute of Cancer Research, London, SW3 6JB, United Kingdom Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey SM2 5NG, U.K. 1Cancer Research UK Centre for Cancer Therapeutics, Institute of Cancer Research, Surrey, United Kingdom and Institute of Cancer Research, Belmont, UK 1Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom and Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, UK 1Cancer Research UK, Centre for Cancer Therapeutics, The Institute of Cancer Research, Belmont, Surrey, United Kingdom; 3The Institute of Cancer Research, London, United Kingdom. Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, SM2 5NG U. K. Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, U.K., and Astex Therapeutics Ltd., 436 Cambridge Science Park, Milton Road, Cambridge CB4 0QA, U.K. 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London SM2 5NG, United Kingdom 1Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey SM2 5NG, U.K. 1Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. Authors' Affiliation: Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, SM2 5NG3, UK Authors' Affiliations: 1Cancer Research UK and EPSRC Cancer Imaging Centre, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust and 2Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Sutton, Surrey, United Kingdom; and 3Translational Oncology Unit Consejo Superior de Investigaciones Cientificas-UAM-La Paz, Centro Nacional de Biotecnología, Madrid, Spain Authors' Affiliations: Divisions of 1Clinical Studies, 2Cancer Therapeutics, and 3Molecular Pathology, The Institute of Cancer Research, Sutton, Surrey; 4Histopathology Department, The Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom; and 5Department of Neuropathology, University of Bonn, Bonn, Germany Authors' Affiliations: 1Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, Sutton, Surrey; and 2Astex Therapeutics, Cambridge, United Kingdom Authors' Affiliations: 1Division of Cancer Therapeutics, 2Division of Radiotherapy and Imaging, The Institute of Cancer Research, Sutton; and 3Sareum Ltd, Cambridge, United Kingdom Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey, SM2 5NG, United Kingdom Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, UK Authors' Affiliations: 1Paediatric Oncology, 2Cancer Research UK Cancer Therapeutics Unit, Institute of Cancer Research; 3Paediatric Oncology, Royal Marsden Hospital, Sutton, United Kingdom; and 4Novartis Pharma, Basel, Switzerland Cancer Research UK Cancer Therapeutics Unit at The Institute of Cancer Research, London, SW7 3RP, U.K. Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, U.K., Cancer Research UK Centre for Cell and Molecular Biology, The Institute of Cancer Research, 237 Fulham Road, London SW3 6JB, U.K., and Astex Therapeutics Ltd., Registered in England at 436 Cambridge Science Park, Cambridge CB4 0QA, U.K. 4Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. Division of Cancer Therapeutics The Institute of Cancer Research London SM2 5NG UK 1Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow and McElwain Laboratories, Sutton, Surrey, United Kingdom and 2Piramed Pharma, Slough, Berkshire, United Kingdom 1Cancer Research UK Centre for Cancer Therapeutics at The Institute of Cancer Research, Haddow Laboratories, Belmont, Sutton, United Kingdom and Authors' Affiliations: 1Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 2Sareum Ltd, Cambridge, United Kingdom Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, SM2 5NG, UK Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London SW7 3RP, UK Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research London, London, UK Drug Metabolism and Pharmacokinetics Team Division of Cancer Therapeutics The Institute of Cancer Research London UK Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom 1Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London, United Kingdom. Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, Sutton, Surrey SM2 5NG, U.K. 6Division of Cancer Therapeutics, Institute of Cancer Research, London, United Kingdom. Cancer Research United Kingdom Cancer Therapeutics Unit, Institute of Cancer Research, Sutton SM2 5NG, United Kingdom; Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, 15 Cotswold Road, Sutton, Surrey SM2 5NG, U.K. 2The Institute of Cancer Research, London, United Kingdom. 1Cancer Research UK Centre for Cancer Therapeutics at the Institute of Cancer Research, Sutton, Surrey, United Kingdom and Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, 15 Cotswold Road, London SM2 5NG, U.K. Authors' Affiliations: 1Cancer Research UK, Cancer Therapeutics Unit, and 2Paediatric Oncology, The Institute of Cancer Research; 3Cancer Research UK and EPSRC Cancer Imaging Centre, The Institute of Cancer Research and Royal Marsden NHS Trust, Sutton, Surrey; and 4Breakthrough Breast Cancer Research Centre, London, United Kingdom 1Cancer Research UK Cancer Therapeutics Unit, The Institute of Cancer Research, London, United Kingdom.; 2Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom. 1Cancer Research UK Centre for Cancer Therapeutics, The Institute of Cancer Research, Haddow and McElwain Laboratories, Sutton, Surrey, United Kingdom; Authors' Affiliations: 1Cancer Research UK Centre for Cancer Therapeutics, 2Section of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 3Section of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, Chelsea, London, United Kingdom; Authors' Affiliations: 1Cancer Research UK Centre for Cancer Therapeutics, 2Section of Cancer Therapeutics, The Institute of Cancer Research, Haddow Laboratories, Sutton, Surrey, United Kingdom and 3Section of Structural Biology, The Institute of Cancer Research, Chester Beatty Laboratories, Chelsea, London, United Kingdom Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, 15 Cotswold Road, Sutton, London, SM2 5NG, United Kingdom Authors' Affiliations: 1Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, Sutton; 2Astex Pharmaceuticals, Cambridge; and 3Cancer Research UK Drug Development Office, Research Operations and Funding, London, United Kingdom Cancer Research UK Cancer Therapeutics Unit, Division of Cancer Therapeutics, The Institute of Cancer Research, London SM2 5NG, United Kingdom; and |
Incoming Links
Total number of triples: 148.